EGEN microRNA Inhibitor Shows Promise in Preclinical Testing | GenomeWeb

EGEN announced this week that its microRNA inhibitor-based treatment for pulmonary arterial hypertension was able to reverse the pulmonary hypertension associated with advanced stages of the disease and restore cardiovascular function in rat models.

According to the company, the drug targets miR-145, which has been linked to vascular remodeling in PAH, and is delivered with a propriatry mPEG nanoparticle that is administered directly to the lung.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: SNP reference panel from the Haplotype Reference Consortium, and more.

Halloran Consulting's Laurie Halloran lists at Stat News the mistakes she sees startup companies make when pursuing a clinical trial.

MIT researchers are using bees to collect and visualize urban microbiome samples, Wired reports.

Reliance on Excel leads to errors in gene name lists, a new Genome Biology paper reports.